You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Disease-Free Survival

Showing 9976 - 10000 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma Trial in Australia, Canada,

Completed
Has Results
  • Localized Resectable Neuroblastoma
  • +4 more
  • Clinical Observation
  • +5 more
  • Birmingham, Alabama
  • +103 more
Jan 4, 2023

Carcinoma, Non-Small Cell Lung Trial (Atezolizumab, Placebo, Carboplatin)

Withdrawn
  • Carcinoma, Non-Small Cell Lung
  • (no location specified)
Jun 14, 2021

Breast Cancer Trial in Rozzano (external beams radiotherapy, brachytherapy)

Recruiting
  • Breast Cancer
  • external beams radiotherapy
  • brachytherapy
  • Rozzano, Milano, Italy
    IRCCS Istituto Clinico Humanitas
Jan 13, 2023

Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes Trial in Worldwide (Inclisiran, Evolocumab)

Completed
  • Atherosclerotic Cardiovascular Disease
  • +3 more
  • Jacksonville, Florida
  • +51 more
Feb 7, 2022

Leiomyosarcoma Trial in Bad Saarow, Berlin (Dinutuximab Beta, Zoledronic acid, Interleukin-2)

Recruiting
  • Leiomyosarcoma
  • Dinutuximab Beta, Zoledronic acid, Interleukin-2
  • Bad Saarow, Germany
  • +1 more
Jun 2, 2022

Gastric Cancer, Stomach Tumor Trial in China (XELOX or SOX, S001+XELOX or SOX)

Recruiting
  • Gastric Cancer
  • Stomach Neoplasm
  • XELOX or SOX
  • S001+XELOX or SOX
  • Fuzhou, Fujian, China
  • +8 more
Jun 18, 2021

Carcinoid Tumor, Pancreatic Neuroendocrine Tumor Trial in Boston (Cabozantinib)

Active, not recruiting
  • Carcinoid Tumor
  • Pancreatic Neuroendocrine Tumor
  • Boston, Massachusetts
  • +1 more
Jul 15, 2022

Relapsed or Refractory Large B-cell Lymphoma Trial in Nashville (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • Relapsed or Refractory Large B-cell Lymphoma
  • Axicabtagene Ciloleucel
  • +3 more
  • (no location specified)
Jul 13, 2022

NHL, DLBCL, Non-hodgkin's Lymphoma Trial in United Kingdom, United States (AZD9150, Acalabrutinib, AZD6738)

Completed
  • NHL
  • +3 more
  • Los Angeles, California
  • +11 more
Aug 11, 2022

Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma Trial in United

Recruiting
  • Embryonal Rhabdomyosarcoma
  • +2 more
  • Birmingham, Alabama
  • +47 more
Aug 17, 2022

Metastatic NSCLC Trial in Worldwide (Volrustomig, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Metastatic Non-small Cell Lung Cancer
  • Rosario, Argentina
  • +51 more
Aug 2, 2023

Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

Active, not recruiting
  • Extranodal NK/T Cell Lymphoma, Nasal Type
  • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
  • Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 10, 2022

NSCLC Trial in Worldwide (Ceritinib, pemetrexed, docetaxel)

Active, not recruiting
Has Results
  • Non-Small Cell Lung Cancer
  • Fayetteville, Arkansas
  • +96 more
Dec 19, 2022

Digestive System Tumors Trial in Hong Kong (EUS-guided RFA)

Recruiting
  • Digestive System Neoplasms
  • EUS-guided RFA
  • Hong Kong, Hong Kong
    Department of Surgery, Prince of Wales Hospital
Aug 2, 2021

Solid Tumor, Microsatellite Instability, Mismatch Repair Deficiency Trial in Australia (APL-501)

Completed
  • Solid Tumor
  • +3 more
  • Camperdown, New South Wales, Australia
  • +4 more
May 5, 2022

BRAF V600E Mutation Trial run by the NHGRI (Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide)

Completed
Has Results
  • BRAF V600E Mutation
  • Dabrafenib Mesylate
  • Trametinib Dimethyl Sulfoxide
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 6, 2021

HCC Trial in China (DEB-TACE and HAIC, DEB-TACE)

Recruiting
  • HCC
  • DEB-TACE and HAIC
  • DEB-TACE
  • Luohe, Henan, China
  • +15 more
Mar 28, 2023

Craniopharyngioma Trial in Jacksonville, Memphis (procedure, device, drug)

Active, not recruiting
  • Craniopharyngioma
  • Radical Surgery or Limited Surgery
  • +3 more
  • Jacksonville, Florida
  • +1 more
Jan 5, 2022

NSCLC Trial in Spain, United Kingdom, United States (Lazertinib)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Duarte, California
  • +8 more
Jan 31, 2023

Metastatic Solid Tumors, Esophageal Cancer, NSCLC Trial in Houston, San Antonio, Toronto (M1231)

Recruiting
  • Metastatic Solid Tumors
  • +2 more
  • Houston, Texas
  • +2 more
Jul 29, 2022

Multiple Myeloma Trial in Worldwide (Carfilzomib Lenalidomide Dexamethasone, Isatuximab Carfilzomib Lenalidomide Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib Lenalidomide Dexamethasone
  • Isatuximab Carfilzomib Lenalidomide Dexamethasone
  • Ostrava, Czechia
  • +6 more
Jul 26, 2022

Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype Trial in Chicago (drug, other, radiation)

Recruiting
  • Astrocytoma
  • +4 more
  • Mycophenolate Mofetil
  • +3 more
  • Chicago, Illinois
    Northwestern University
Aug 22, 2022

Cholangiocarcinoma Trial in Brussels, Beirut, Luxembourg (BMS-936558)

Terminated
  • Cholangiocarcinoma
  • Brussels, Belgium
  • +3 more
Feb 7, 2022

Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell Trial in United States (ABT-199 and Ibrutinib Combination)

Completed
  • Lymphoma, Mantle-Cell
  • Recurrent Lymphoma, Mantle-Cell
  • ABT-199 and Ibrutinib Combination
  • Duarte, California
  • +3 more
May 22, 2022

Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Tumors Trial in Houston (BP1001-A (Liposomal Grb2 Antisense

Not yet recruiting
  • Solid Tumor, Adult
  • +5 more
  • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)
  • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
  • (no location specified)
Jun 7, 2022